Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
66. |
ECCT/23/01/04 | ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Lucas Tina Otieno Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria Biomedical Research Institute, (Kisumu county) 3. Kenya Medical Research Institute/Walter Reed Project (Kericho county) 4. Kenyatta National Hospital (Nairobi City county) 5. Ahero Clinical Trials Unit, (Kisumu county) 6. KEMRI CCR – BUTERE SITE (Kakamega county) |
View |
67. |
ECCT/22/11/04 | YWF:03 YWF:03: A PHASE III, MULTICENTER, DOUBLE BLIND, RANDOMIZED STUDY OF SII YELLOW FEVER VACCINE TO COMPARE SAFETY AND IMMUNOGENICITY WITH STAMARIL® |
Principal Investigator(s) 1. Videlis Nduba 2. Otieno Walter Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
68. |
ECCT/23/01/01 | PROHER A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2-POSITIVE BREAST CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
69. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |
70. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |